trametinib dimethyl sulfoxide

https://www.pharmaceutical-technology.com/data-insights/trametinib-dimethyl-sulfoxide-novartis-relapsed-multiple-myeloma-likelihood-of-approval/

Trametinib dimethyl sulfoxide is under clinical development by Novartis and currently in Phase II for Relapsed Multiple Myeloma.

Robuta